We are delighted to announce the selection of the c4c consortium’s first portfolio of pan-European paediatric studies aimed at advancing the understanding of high priority medicines commonly used in babies, children and young people in Europe. The four inaugural studies will be conducted by academic institutions, in addition to three or four studies by industry partners, covering different diseases and age groups.
The selected studies will implement new ways to:
• Ensure that the experiences and preferences of children and young people are reflected in clinical trial design and minimise the burden of their participation in research
• Employ cutting-edge science and implement new, innovative ways to evaluate medicines
• Demonstrate the value of collaborating across 18 countries, building on a public-private partnership that blends expertise from leading industry and academic partners.
Coordinated by Penta, the c4c (conect4children) project is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population. c4c strives to bring innovative processes to all stages of clinical development by generating a new model of organization and of the clinical development process.
For more information please read the full press release here.